Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like T*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020018030	ALUNBRIG 180 MG TABLET * 30 PACK	01/06/2025	606.00	20793.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020011330	ALUNBRIG 30 MG TABLET * 30 PACK	01/06/2025	202.00	6934.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020009030	ALUNBRIG 90 MG TABLET * 30 PACK	01/06/2025	606.00	20793.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020009007	ALUNBRIG 90 MG TABLET * 7 PACK	01/06/2025	142.00	4855.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020019830	ALUNBRIG INITIATION PACK - 7 CT 90 MG TABLET and 23 CT 180 MG TABLET - PER PACK	01/06/2025	606.00	20793.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/28/2025	64764030020	Entyvio Intravenous Solution Reconstituted 300 MG	01/01/2025	693.33	9359.91	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020053630	ICLUSIG 10 MG TABLET * 30 PACK	01/06/2025	871.00	22640.00	12/12/2033	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020053530	ICLUSIG 15 MG TABLET * 30 PACK	01/06/2025	871.00	22640.00	12/12/2033	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020053330	ICLUSIG 30 MG TABLET * 30 PACK	01/06/2025	871.00	22640.00	12/12/2033	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020053430	ICLUSIG 45 MG TABLET * 30 PACK	01/06/2025	871.00	22640.00	12/12/2033	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020023002	NINLARO 2.3 MG CAPSULE * 3 PACK	01/06/2025	390.00	13364.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020023001	NINLARO 2.3 MG CAPSULE * SINGLE PACK	01/06/2025	130.00	4458.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020039002	NINLARO 3.0 MG CAPSULE * 3 PACK	01/06/2025	390.00	13364.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020039001	NINLARO 3.0 MG CAPSULE * SINGLE PACK	01/06/2025	130.00	4458.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020040002	NINLARO 4.0 MG CAPSULE * 3 PACK	01/06/2025	390.00	13364.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020040001	NINLARO 4.0 MG CAPSULE * SINGLE PACK	01/06/2025	130.00	4458.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000232	TerSera Therapeutics LLC	04/16/2025	74527002202	Margenza Intravenous Solution 250 MG/10ML (25 MG/ML), 10 ML, Unit-Dose, 1 Vial	02/01/2025	233.84	2595.81	12/02/2041	Single Source Drug	None	None	None	1	None	1	None	1	11/12/2024	MacroGenics, Inc.	40000000	None	None	2361.97	2248.16	2021	2077.00	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	74527002203	Margenza Intravenous Solution 250 MG/10ML, (25 MG/ML), 10 ML, Unit-Dose, 4 Vials	02/01/2025	935.34	10383.22	12/02/2041	Single Source Drug	None	None	None	1	None	1	None	1	11/12/2024	MacroGenics, Inc.	40000000	None	None	9447.88	8992.64	2021	8308.00	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720072010	Prialt Intrathecal Solution 100 MCG/1 ML, Unit-Dose, 1 Vial	01/01/2025	54.56	1167.92	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720072310	Prialt Intrathecal Solution 500 MCG/20ML (25 MCG/ML), 20 ML, Unit-Dose, 1 Vial	01/01/2025	258.88	5542.14	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720072210	Prialt Intrathecal Solution 500 MCG/5ML, 5 ML, Unit-Dose, 1 Vial	01/01/2025	258.88	5542.14	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720010025	Quzyttir Intravenous Solution 10 MG/ML, 1 ML, Unit-Dose, 25 Vials	01/01/2025	404.00	8646.50	02/28/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720010010	Quzyttir Intravenous Solution 10 MG/ML, 1 ML, Unit-Dose, Vial	01/01/2025	16.69	357.38	02/28/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720012585	Xermelo Oral Tablet 250 MG, 84 Each, Unit-of-Use, 1 Box	01/01/2025	948.46	10528.82	02/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	09/08/2020	Lexicon Pharmaceuticals, Inc.	159000000	None	None	6559.00	6253.00	2017	5164.00	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720095130	Zoladex Subcutaneous Implant 10.8 MG, 1 Each, Unit-of-Use, 1 Box	01/01/2025	136.39	2920.02	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720095036	Zoladex Subcutaneous Implant 3.6 MG, 1 Each, Unit-Dose, 1 Syringe	01/01/2025	58.58	1051.40	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000302	Tetraphase Pharmaceuticals	04/29/2025	71773010012	Xerava 12 (10 mL) SDVs 100 mg Injection, Powder, Lyophilized, for Solution	01/02/2025	80.00	1400.00	10/19/2037	Single Source Drug	None	None	None	1	Our drugs target rare diseases and serve smaller patient populations, meaning that the costs of development and manufacturing must be spread over fewer patients, leading to the need for higher prices.  Our comprehensive evaluation included other similar drugs and we compared that analysis with pharmacoeconomics to make the decision to raise our price.	None	A change or improvement in the product does not necessitate the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000302	Tetraphase Pharmaceuticals	04/29/2025	71773005012	Xerava 12 (10 mL) SDVs 50 mg Injection, Powder, Lyophilized, for Solution	01/02/2025	67.00	805.00	10/19/2037	Single Source Drug	None	None	None	1	Our drugs target rare diseases and serve smaller patient populations, meaning that the costs of development and manufacturing must be spread over fewer patients, leading to the need for higher prices.  Our comprehensive evaluation included other similar drugs and we compared that analysis with pharmacoeconomics to make the decision to raise our price.	None	A change or improvement in the product does not necessitate the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000217	Teva Neuroscience, Inc.	04/29/2025	68546014256	AZILECT 0.5MG TABLET 30 EACH	01/01/2025	107.50	1251.10	08/27/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	04/29/2025	68546022956	AZILECT 1MG TABLET 30 EACH	01/01/2025	107.50	1251.10	08/27/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844011001	ADDERALL 10MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844011201	ADDERALL 12.5MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844011501	ADDERALL 15MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844012001	ADDERALL 20MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844013001	ADDERALL 30MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844010501	ADDERALL 5MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844011701	ADDERALL 7.5MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844014001	ADIPEX-P TABLETS 100 EA	01/01/2025	25.60	297.96	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844014056	ADIPEX-P TABLETS 30 EA	01/01/2025	5.95	69.22	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459070060	AMRIX 15 MG XR CAPSULE 60EA	01/01/2025	327.30	3809.70	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459070160	AMRIX 30 MG XR CAPSULE 60EA	01/01/2025	327.30	3809.70	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	52544008001	FIORICET ORAL CAPS 50/300/40 MG 100 EA	01/01/2025	72.30	841.90	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	52544008201	FIORICET ORAL CAPs 50/300/40/30 MG 100 EA	01/01/2025	151.50	1762.70	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844021552	GALZIN 25 MG CAPSULE 250 EA	01/01/2025	53.30	620.80	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844020852	GALZIN 50 MG CAPSULE 250 EA	01/01/2025	88.90	1034.60	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	00575620030	PROGLYCEM ORAL SUS 50MG/ML 30ML	01/01/2025	41.80	486.60	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459010130	PROVIGIL 100MG 30 EA	01/01/2025	143.80	1674.10	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459020130	PROVIGIL 200MG 30 EA	01/01/2025	217.30	2529.50	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459060106	TRISENOX VIAL 2 MG/ML 6 ML 10 VIAL	01/01/2025	1096.60	12762.80	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285013197	LOESTRIN 21 1.0MG/20MCG TABLET 105 EA	01/01/2025	93.40	1087.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285012797	LOESTRIN 21 1.5MG/30MCG TABLET 105 EA	01/01/2025	93.40	1087.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285012870	LOESTRIN FE 28 1.5MG/30MCG TABLET 140 EA	01/01/2025	93.40	1087.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285012570	LOESTRIN FE 28 1MG/20MCG TABLET 140 EA	01/01/2025	93.40	1087.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285036801	TREXALL 10 MG TABLET 30EA	01/01/2025	118.90	1383.80	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285036901	TREXALL 15 MG TABLET 30EA	01/01/2025	178.40	2075.80	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285036601	TREXALL 5 MG TABLET 30EA	01/01/2025	59.50	692.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285036701	TREXALL 7.5 MG TABLET 30EA	01/01/2025	89.20	1037.90	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000573	The Harvard Drug Group, L.L.C. dba Major Pharmaceuticals	04/08/2025	00904714461	Dronabinol 2.5mg Cap Unit Dose 10X10	04/01/2025	377.25	849.60	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000573	The Harvard Drug Group, L.L.C. dba Major Pharmaceuticals	04/08/2025	00904714504	Dronabinol 5mg Cap Unit Dose 3X10	04/01/2025	226.52	515.77	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000395	Travere Therapeutics, Inc.	04/09/2025	68974020030	Filspari 200 mg Tablet 30 count Bottle	02/10/2025	692.64	12432.27	03/29/2030	Single Source Drug	None	None	None	1	Travere routinely assesses the prices of its medicines to determine if they remain appropriate, taking into account the value delivered, the price of other medicines available and increases in our costs. As part of our overall approach to pricing medicine, we also work with payers and patient organizations to ensure that any price adjustment does not present a barrier to access.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000395	Travere Therapeutics, Inc.	04/09/2025	68974040030	Filspari 400 mg Tablet 30 count Bottle	02/10/2025	692.64	12432.27	03/29/2030	Single Source Drug	None	None	None	1	Travere routinely assesses the prices of its medicines to determine if they remain appropriate, taking into account the value delivered, the price of other medicines available and increases in our costs. As part of our overall approach to pricing medicine, we also work with payers and patient organizations to ensure that any price adjustment does not present a barrier to access.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000618	Trifluent Pharma LLC	04/29/2025	73352045501	HYDROCORTISONE TOPICAL SOLUTION 2.5% 30ML	01/06/2025	253.50	1238.00	None	Non-innovator Multiple Source Drug	None	None	635434	None	Very shortly after we launched two products, we discovered an issue in our systems that led to a pricing error. We immediately filed a pricing correction on 1/6 for both products.	None	n/a	None	12/16/2024	Mission Pharmacal	None	1	None	204.23	204.23	2011	204.23	None	None
Rx0000618	Trifluent Pharma LLC	04/29/2025	73352084530	TRIDACAINE XL LIDOCAINE 5% PATCH 30CT	01/06/2025	744.00	1540.00	None	Non-innovator Multiple Source Drug	None	None	16601	None	Very shortly after we launched two products, we discovered an issue in our systems that led to a pricing error. We immediately filed a pricing correction on 1/6 for both products.	None	n/a	None	12/01/2024	Yaral	None	1	None	85.50	85.50	2023	85.50	None	This product was a repackaged product.